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I.  INTRODUCTION
Kathy Hopkins was the eldest of seven children.  She was a single mother, and 
the sole supporter of her son.  In the spring of 2007, Kathy was diagnosed with stage 
four glioblastoma multiform (“GBM”).  GBM is a compilation of small tumors 
within the glia or the precursors of the glia within the central nervous system.1 This 
form of brain cancer is “the most aggressive of the glimoas.”2  Most individuals with 
                                                          
* J.D. Cleveland State University, Cleveland-Marshall College of Law, 2013; B.S. John 
Carroll University, 2010. Thank you to my loving family and friends for their continuous 
support. A special thank you to Lisa Gasbarre Black, Esq., my mentor and dear friend.  Lastly, 
I would like to dedicate this Note to the memory of my beloved Aunt Katherine Hopkins.  
1 Eric C. Holland, Glioblastoma Multiforme: The Terminator, 97(12) PNAS 6242, 6242 
(2000), available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC33993/pdf/pq006242.pdf.  
2 Id. The medical community has “evaded increasingly clever and intricate attempts at 
therapy over the last half-century.” Id. The latest treatment implements “a hybrid virus that 
infects and kills clonal human glioma cell lines.” Id. This treatment has been tested in athymic 
mice successfully “without affecting nonneoplastic cells within the brain.”  Id.   
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GBM die in less than a year from the date of diagnosis.3  Even with treatment, the 
life expectancy of individuals diagnosed with GBM only increases from two months 
to a year.4 Kathy’s tumor was inoperable. Her only options for treatment included 
chemotherapy and radiation. Determined that the medical community would 
discover a cure, Kathy chose to try every medical procedure available in hopes that 
she could defeat GBM. On April 1, 2009, two years after her diagnosis, at the age of 
63, Kathy passed away surrounded by her loving family.5  
Greg Knittel was the Classics’ Chairman, Dean of Teachers, and founding soccer 
coach at St. Ignatius High School in Cleveland, Ohio.6 Greg, fondly known by his 
students and the Ignatius community as “Doc,” was forced to retire from St. Ignatius 
when he lost the ability to control his car on his drive into work.7  Greg was 
suffering from amyotrophic lateral sclerosis (“ALS”).8 The major cause(s) of ALS, 
also commonly referred to as Lou Gehrig’s9 disease, are unknown.10 Ten percent of 
all ALS cases are genetically based.11 ALS causes neurons12 to slowly waste away 
                                                          
3 Id.  
4 Id. 
5 The story of Kathy Hopkins was taken from the author’s personal experiences. 
6 Grant Segall, Greg Knittel was Dean, Chairman and Soccer Coach at St. Ignatius: 
News Obituary, CLEVELAND PLAIN DEALER, Feb. 8, 2013, http://www.cleveland.com/obitu 
aries/index.ssf/2013/02/greg_knittel_was_dean_chairman.html (last visited Feb. 17, 2013).  
Greg had an extensive educational and extracurricular background.  Id.  
He attended College of the Holy Cross in Worcester, Mass. He earned a bachelor’s 
degree from John Carroll University and went on to a master’s at the University of 
California at Santa Barbara. He taught at high school in Santa Barbara for two years.  
Knittel rejoined Ignatius in 1974 to teach classics and started the soccer team two 
years later. He stopped coaching in 1985 to earn a doctorate from Kent State 
University. He coached again from 1990 through 1994. His teams had 161 wins, 61 
losses and 31 ties. He was inducted into the school’s Athletic Hall of Fame twice: as 
coach and as part of the 1964 football team, which was inducted as a group. He was 
twice named area soccer coach of the year and once Ignatius’ teacher of the year. 
Id.   
7 Id. 
8 Gregory Joseph “Doc” Knittel Ph.D, Obituaries & Guestbook, CLEVELAND PLAIN 
DEALER, Feb 8, 2013, http://obits.cleveland.com/obituaries/cleveland/obituary.aspx?n=gre 
gory-joseph-knittel-doc&pid=162929249&fhid=15566#fbLoggedOut; Amyotrophic Lateral 
Sclerosis: Lou Gehrig’s Disease; ALS; Upper and Lower Motor Neuron Disease; Motor 
neuron disease, PUBMED HEALTH, http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001708/ 
(last updated Aug. 26, 2012).  
9 Henry Louis Gehrig played for the New York Yankees during the 1920s and 1930s.  
Lou Gehrig, BIOGRAPHY.COM, http://www.biography.com/people/lou-gehrig-9308266?page=1 
(last visited Feb. 17, 2013). A member of the Baseball Hall of Fame, Gehrig as a Yankees first 
basemen set the mark for consecutive games played until he was forced to retire due to ALS.  
Id. “His diagnosis with the disease helped put the spotlight on the condition, and in the years 
since Gehrig's passing, it has come to be known popularly as ‘Lou Gehrig's disease.’” Id.   
10 Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8.  
11 Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8. 
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and eventually die, resulting in “muscle weakening, twitching, and eventually the 
inability to move the arms, legs, and body.”13 This is caused by the inability of 
neurons to “send messages to [the] muscles” of the body after neurons have died.14  
Individuals with ALS typically die within three to five years after being diagnosed.15  
Only about twenty five percent of individuals diagnosed with ALS live beyond five 
years.16 On February 5, 2013 Greg “Doc” Knittel passed away surrounded by his 
loving family.17   
Kathy and Greg are only two individuals, out of millions, who have suffered or 
who are currently suffering from incurable diseases. Scientists are in a race to 
discover new diagnostic technologies and treatments to bring an end to human 
anguish through the rapidly growing field of genetics. While cures are within the 
grasp of humanity’s fingertips, current gene patent regulations act as roadblocks to 
                                                          
12 A neuron is  “[a]ny of the impulse-conducting cells that constitute the brain, spinal 
column, and nerves, consisting of a nucleated cell body with one or more dendrites and a 
single axon. Also called nerve cell.” Neuron, FREE ONLINE DICTIONARY, THESAURUS, AND 
ENCYCLOPEDIA, http://www.thefreedictionary.com/neuron (last visited Nov. 24, 2011).  
13 Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8.  
14 Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8. 
15 Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8. 
16 Amyotrophic lateral sclerosis: Lou Gehrig’s Disease, supra note 8. 
17 The story of Greg “Doc” Knittel was taken from the author’s personal experiences.  
Another ALS story is that of Jim Ziegler: 
Jim Ziegler was a humble, generous man who made his mark on the world for the 62 
years he was a part of it.  In the summer of 2010, Jim began experiencing muscle 
pains in his legs, particularly when engaging in physical activity. On one occasion, his 
friends had to carry him off the golf course because the pain became so severe that it 
was unbearable for Jim to walk. Jim visited his doctor that fall and spoke of the 
symptoms he had been experiencing, and it was on that day that his fate was 
confirmed. At the age of 61, my uncle was diagnosed with ALS. Jim’s diagnosis came 
in September of 2010, and he passed away on April 29, 2011. The case my uncle 
suffered from was especially aggressive, and stole his ability to walk or even move his 
arms and legs within a few months of his diagnosis. For as much pain and suffering 
that he went through with this terrible disease, Jim was incredibly patient and willing 
to accept his fate. For as quickly as the disease progressed through Jim’s body, it took 
him away from us just as swiftly. In honor of Jim Ziegler and the legacy he left 
behind, our family has participated in the Walk to Defeat ALS in hopes of 
contributing to fund future research that will find a will cure to this debilitating and 
fatal disease. 
Interview with Riannon Ziegler, Third Year Law Student, Cleveland-Marshall College of 
Law, Cleveland State University, Cleveland, Ohio (Jan. 13, 2013). The ALS Association is 
one of  “the largest privately-funded research enterprise[s] engaged to uncover the mystery of 
a disease that affects as many as 30,000 annually.” About Us, Walk to Defeat ALS, THE ALS
ASSOCIATION, http://web.alsa.org/site/PageServer?pagename=WLK_BP_aboutus (last visited 
Feb. 18, 2013). Over the past 10 years, the ALS Association has contributed about forty-eight 
million dollars to research.  Id.  “The ALS Association symbolizes the hopes of people 
everywhere that [ALS] will one day be a disease of the past relegated to historical status, 
studied in medical textbooks, conquered by the dedication of thousands who have worked 
ceaselessly to understand and eradicate this perplexing killer.”  Id.    
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uncovering such discoveries. Gene patents have long been a topic of debate, first 
with the discovery of DNA, and later with the Human Genome Project and the 
HapMap Project, which resulted in the discovery of the complete sequence of the 
human genome and further discoveries of gene sequences.18   
In September, 2011, the Senate passed H.R. 1249, the Leahy-Smith America 
Invents Act (“AIA”), which President Barrack Obama signed into law on September 
16th.19 The AIA is the largest transformation to U.S. patent law since 1952.20 While 
the new legislation implements numerous, positive changes to the U.S. patent 
system, it fails to address any of the concerns raised by gene patent critics over the 
past few decades.21 Gene patents should be categorized as patentable subject matter 
within the AIA, but under a separate patent category with specifically engineered 
regulations designed to promote scientific research and collaboration that will in turn 
foster quicker results in diagnostic technologies and treatments.   
Part I of this Note provides an educational background on genetics. Part II 
provides a background on the U.S. patent system, taking a historical look at patent 
legislation and case law, as well as the societal views surrounding gene patents. In 
general, this section analyzes the debate on whether genetic materials are patentable 
subject matter within the scope of 35 U.S.C. § 101.  Part III lays a foundation of the 
AIA, and examines whether the new patent legislation properly regulates gene 
patents to stimulate and regulate scientific research and development. Part IV 
analyzes the need for new regulations specifically designed for gene patents within 
the AIA, and proposes detailed guidelines to achieve stricter, more appropriate 
regulations for gene patents.   
                                                          
18 International Consortium Launches Genetic Variation Mapping Project: HapMap will 
Help Identify Genetic Contributions to Common Diseases, NATIONAL HUMAN GENOME 
RESEARCH INSTITUTE, http://www.genome.gov/10005336 (last visited Oct. 24, 2011).   
The genome is an organism’s complete set of DNA. Genomes vary widely in size: the 
smallest known genome for a free-living organism (a bacterium) contains about 
600,000 DNA base pairs, while human and mouse genomes have some 3 billion. 
Except for mature red blood cells, all human cells contain a complete genome.  
From the Genome to the Proteome, HUMAN GENOME PROJECT SCIENCE, http://www.ornl.gov/ 
sci/techresources/Human_Genome/project/info.shtml (last visited Oct. 24, 2011).  
19 President Obama Signs America Invents Act, Overhauling the Patent System to 
Stimulate Economic Growth, and Announces New Steps to Help Entrepreneurs Create Jobs, 
THE WHITE HOUSE (Sept. 16, 2011), http://www.whitehouse.gov/the-press-office/2011/09/16 
/president-obama-signs-america-invents-act-overhauling-patent-system-stim (last visited Oct. 
10, 2011).  
20 1-1 CHISUM ON PATENTS §1.01 (LexisNexis 2011). 
21 Compare Eric D. Zard, Patentability of Human Genetic Information: Exploring Ethical 
Dilemmas Within the Patent Office and Biotechnology’s Clash with the Public Good, 6 U. ST.
THOMAS L.J. 486, 493 (2009) (establishing the concerns regarding gene patents), with The 
Leahy-Smith America Invents Act, H.R. 1249, 120th Cong. (2011) (enacted), reprinted in
www.uspto.gov/aia_implementation/bills-112hr1249enr.pdf (failing to address the concerns 
established by critics of gene patents).  
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II.  GENETICS 101: BASIC EDUCATIONAL FOUNDATION
A.  Dissecting the Double Helix of Deoxyribonucleic Acid  
An organism’s complete set of deoxyribonucleic acid (DNA)22 is known as its 
genome.23  DNA is arranged in the nucleus of each cell within the human body.24  
Each nucleus contains two sets of chromosomes, one set given by each parent, for a 
total of forty-six chromosomes. 25 Each chromosome contains a single strand of 
DNA.26 The DNA double helix is a linear arrangement of repeating nucleotides.27  
Nucleotides are composed of one sugar, one phosphate, and a nitrogenous base.28  A 
nucleotide can contain one of four nitrogenous bases: adenine (A), guanine (G), 
cytosine (C), or thymine (T).29  These bases pair up with one another, A with T, and 
C with G, to form base pairs.30 The order of these base pairs “determines the 
information available for building and maintaining an organism, similar to the way 
in which letters of the alphabet appear in a certain order to form words and 
sentences.”31  
A gene is “a specific sequence of nucleotides in DNA” found on a 
chromosome.32 The specific sequence of nucleotides “determine[s] how, when, and 
where the body makes each of the many thousands of different proteins required for 
                                                          
22 DNA is the hereditary material found in all multi-celled organisms. An Overview of the 
Human Genome Project, NATIONAL HUMAN GENOME RESEARCH INSTITUTE, http://www.gen 
ome.gov/12011238 (last visited Oct. 25, 2011).    
23 From the Genome to the Proteome, supra note 18. Deoxyribonucleic acid (“DNA”) was 
first identified by Friedrich Miescher, a Swiss chemist, in the late 1860s. Leslie A. Pray, 
Discovery of DNA Structure and Function: Watson and Crick, NATURE EDUCATION, 
http://www.nature.com/scitable/topicpage/discovery-of-dna-structure-and-function-watson-
397 (last visited Oct. 24, 2011). Friedrich Miescher identified what he termed a “nuclein” 
inside the nuclei of a human white blood cell.  Id. “The term ‘nuclein’ was later changed to 
‘nucleic acid’ and eventually to ‘deoxyribonucleic acid,’ or ‘DNA.’” Id. In addition to 
Miescher’s contributions, Phoebus Levene and Erwin Chargaff research uncovered the 
primary chemical components of DNA, as well as how each chemical component joins with 
one another. Id.  In 1953, James Watson and Francis Crick discovered the three-dimensional 
double helix structure of DNA.  Id. 
24 Handbook: Help Me Understand Genetics, GENETICS HOME REFERENCE 9, http://ghr 
.nlm.nih.gov/handbook.pdf (last visited Feb. 18, 2013).  
25 Id. at 15.  
26 Chromosomes FAQs, HUMAN GENOME PROJECT INFORMATION, http://www.ornl.gov/sc 
i/techresources/Human_Genome/posters/chromosome/faqs.shtml (last visited Nov. 24, 2011). 
27 Id.
28 Id.  
29 Handbook: Help Me Understand Genetics, supra note 24, at 9.  
30 Handbook: Help Me Understand Genetics, supra note 24, at 9.  
31 Handbook: Help Me Understand Genetics, supra note 24, at 9.  
32 Gene, MERRIAM-WEBSTER ONLINE DICTIONARY, http://www.merriam-webster.com/dic 
tionary/gene (last visited Oct. 24, 2011).  
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life.”33 “Genes make up less than [two] percent of human DNA.”34 The remaining 
DNA has important functions; however, those functions are still unknown.35 It is 
speculated that those functions could “include regulating genes and maintaining the 
chromosome structure.”36 When a nitrogenous base changes within the nucleotide of 
a gene, disorders and diseases result.37 For example, “cystic fibrosis38 (chromosome 
7) and sickle cell anemia39 (chromosome 11) are caused by base sequence changes in 
a single gene.”40Common diseases, such as cancer and diabetes, have complex 
causes that could be the result of base sequence changes on several genes 
encompassing several chromosomes.41In 1990, a project called the Human Genome42
Project was orchestrated to learn more about the makeup of human DNA and genetic 
material.43   
B.  The Human Genome Project  
The Human Genome Project (“HGP”) was a collaborative, international research 
project aimed at producing a complete map of the human genome.44 The project was 
                                                          
33 Chromosome FAQs, supra note 26.  
34 Chromosome FAQs, supra note 26.
35 Chromosome FAQs, supra note 26. 
36 Chromosome FAQs, supra note 26. 
37 Chromosome FAQs, supra note 26. 
38 Cystic Fibrosis, commonly referred to as CF, “is caused by a defective gene which 
causes the body to produce abnormally thick and sticky fluid, called mucus,” that builds up in 
the lungs and pancreas.  Cystic Fibrosis, PUBMED HEALTH, http://www.ncbi.nlm.nih.gov/pub 
medhealth/PMH0001167 (last visited Feb. 17, 2013). The collection of mucous in the 
respiratory system and pancreas “results in life-threatening lung infections and serious 
digestion problems.” Id. The average lifespan of individuals with CF is about thirty-seven.  
Individuals with CF typically die due to lung complications.  Id.   
39 Sickle cell anemia is a genetic disease that results in an abnormal crescent or sickle 
shaped red blood cell.  Sickle Cell Anemia, PUBMED HEALTH, http://www.ncbi.nlm.nih.gov/pu 
dmedhealth/PMH0001554/ (last visited Feb. 18, 2013). Normally, red blood cells are shaped 
like a disc. Id. Individuals with sickle cell anemia have an abnormal type of hemoglobin 
known as hemoglobin S. Id. Hemoglobin is a protein that carries oxygen that is located within 
a red blood cell. Id. “Sickle cell disease is much more common in people of African and 
Mediterranean descent.”  Id.   
40 Chromosome FAQs, supra note 26. 
41 Chromosome FAQs, supra note 26. 
42 An organism’s complete set of DNA is known as its genome. From the Genome to the 
Proteome, supra note 18.  
43 An Overview of the Human Genome Project, supra note 22. 
44 An Overview of the Human Genome Project, supra note 22. The United States National 
Institute of Health (NIH) and the Department of Energy funded the HGP. The Human Genome 
Project: A New Reality, WELLCOME TRUST SANGER INSTITUTE, http://www.sanger.ac.uk/about/ 
history/hgp/ (last visited Feb. 18, 2013). Specifically the goals for HGP included the 
following: (1) to identify the 20,000-25,000 genes in the human genome; (2) to determine the 
sequences of the nitrogenous base pairs that make up the human DNA; (3) to store the 
gathered information in a database; (4) “to improve tools for data analysis;” (5) “to transfer 
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expected to take fifteen years, but was completed in 2003.45 The HGP decoded the 
human genome in three ways.46 First, it determined the sequence of all the 
nitrogenous bases that comprise DNA.47 Second, it produced maps of gene locations 
and sections of chromosomes.48 Third, it produced linkage maps to track inherited 
traits over generations.49 The full genetic sequence of the human genome was 
completed in April 2003, which revealed about 20,500 human genes.50 Knowledge 
regarding the make-up of DNA and the sequences that compose genes has and will 
continue to lead to revolutionary mechanisms in research, technology, diagnoses, 
treatments, and preventive measures in healthcare, and within medical fields.51   
                                                          
the related technologies to the private sector, and” (6) “to address the ethical, legal, and social 
issues that arise from the project.” About Human Genome Project, HUMAN GENOME PROJECT 
INFORMATION, http://www.ornl.gov/sci/techresources/Human_Genome/project/about.shtml 
(last visited Oct. 25, 2011). While the HGP was being launched, John Sulston in the UK 
began  “mapping the genome of [a] nematode worm . . . .” The Human Genome Project: A 
New Reality, supra note 44. Sulston approached the Wellcome Trust to form a new 
partnership, at which time Wellcome suggested Sulston and his group get involved in the 
HGP.  Id.  By the end of 1993, Sulston and his group of scientists began assisting in the quest 
of the HGP.  Id.   
45 About Human Genome Project, supra note 44.  
46 An Overview of the Human Genome Project, supra note 22. Researchers used the 
hierarchal shotgun method to accurately sequence the human genome.  The Human Genome 
Project: A New Reality, supra note 44. “Researchers agreed that this was the best way to 
achieve the Human Genome Project’s target of 95% coverage of the human genome by 2005.”  
The Human Genome Project: A New Reality, supra note 44. There are two main strategies 
when it comes to sequencing a genome. The first method is the hierarchical shotgun method 
as implemented by the HGP.  The Human Genome Project: A New Reality, supra note 44.  
The second method is the shotgun sequencing method:
The advantage to the hierarchical approach is sequencers are less likely to make 
mistakes when assembling the shotgun fragments into contigs as long as full 
chromosomes.  The reason is that the chromosomal location for each BAC is known, 
and there are fewer random pieces to assemble.  The disadvantage to this method is 
time and expense.  The shotgun method is faster and less expensive, but it is more 
prone to errors due to incorrect assembly of finished sequence. 
The Human Genome Project: A New Reality, supra note 44.  The size and complexity of the 
genome is what determines which sequencing method is better to use.  The Human Genome 
Project: A New Reality, supra note 44.   
47 An Overview of the Human Genome Project, supra note 22.
48 An Overview of the Human Genome Project, supra note 22.
49 An Overview of the Human Genome Project, supra note 22.   
50 An Overview of the Human Genome Project, supra note 22. The number of genes found 
by the HGP was significantly less than what had been estimated by researchers.  An Overview 
of the Human Genome Project, supra note 22. Researchers believed that between 50,000 and 
140,000 genes existed within the human genome. An Overview of the Human Genome 
Project, supra note 22.
51 An Overview of the Human Genome Project, supra note 22.   
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C.  The HabMap Project  
Concurrently with the HGP, the International HapMap52 Consortium launched 
the International HapMap Project (HapMap Project) in 2002.53 The HapMap Project 
was “aimed at speeding [up] the discovery of genes related to common illnesses [and 
diseases].”54  Uncovering the genetic variations that lead to common diseases such as 
Alzheimer’s, cancer, and diabetes is difficult because these disorders are caused by 
variations in multiple genes versus a single variation within one gene.55 The 
variations in the nitrogenous bases within DNA are called single nucleotide 
polymorphisms (SNPs).56 A set of SNPs found on the same chromosome is known 
as a haplotype.57 The HapMap Project produced a public database of the SNPs and 
haplotypes that the project uncovered in order to share the results internationally 
with other scientists.58 Scientists use SNPs and haplotypes to compare the genetic 
differences between healthy individuals and individuals with common diseases.59 By 
                                                          
52 “HapMap stands for ‘Haplotype Map.’” You and the $1000 Genome Part II: The 
International HapMap Project, THE GENETIC GENEALOGIST, http://www.thegeneticgenealo 
gist.com/2007/05/24/you-and-the-1000-genome-%E2%80%93-part-ii-the-international-hapma 
p-project/ (last visited Nov. 7, 2011).  
53 David Secko, Phase I of HapMap Complete, THE SCIENTIST: MAGAZINE OF HEALTH 
SCIENCES, http://classic.the-scientist.com/news/20051026/01/ (last visited Oct. 24, 2011).  
54 International Consortium Launches Genetic Variation Mapping Project: HapMap will 
Help Identify Genetic Contributions to Common Diseases, supra note 18. The HapMap 
Program is a catalogue of SNPs “that maps the natural organization of the human genome in 
blocks called haplotypes.” David Secko, supra note 53.   
During the study, researchers took 296 DNA samples from four populations in 
Nigeria, Tokyo, Beijing, and Utah, aiming to genotype one SNP for every 5kb of 
genome. They characterized over one million SNPs, verified the low haplotype 
diversity in the above populations, and created a fine-scale genetic map of 21, 617 
recombination hotspots.   
Id.  The second phase of the HapMap Project “analyzed an additional 2.1 million[] SNPs.”  Id.
55 International Consortium Launches Genetic Variation Mapping Project: HapMap will 
Help Identify Genetic Contributions to Common Diseases, supra note 18.  
56 International Consortium Launches Genetic Variation Mapping Project: HapMap will 
Help Identify Genetic Contributions to Common Diseases, supra note 18.  
57 Haplotype, NATIONAL HUMAN GENOME RESEARCH INSTITUTE, http://www.genome.gov 
/Glossary/index.cfm?id=99 (last visited Oct. 25, 2011). A haplotype is “a set of DNA 
variations, or polymorphisms, that tend to be inherited together.” Id. “A haplotype can refer to 
a combination of alleles or to a set of single nucleotide polymorphisms (SNPs) found on the 
same chromosome. Information about haplotypes is being collected by the International 
HapMap Project and is used to investigate the influence of genes on disease.”  Id.  
58 Secko, supra note 53.  
59 International Consortium Launches Genetic Variation Mapping Project: HapMap will 
Help Identify Genetic Contributions to Common Diseases, supra note 18. This method of 
research is known as an association study. International Consortium Launches Genetic 
Variation Mapping Project: HapMap will Help Identify Genetic Contributions to Common 
Diseases, supra note 18. “If the association study finds a certain haplotype more often in the 
people with the disease, researchers would then zero in on that genomic region in their search 
for the specific genetic variant. The tag SNPs would serve as signposts indicating that a 
384 JOURNAL OF LAW AND HEALTH [Vol. 26:375 
looking at the differences in genetic variations between individuals with a disease 
and healthy individuals, researchers can uncover the specific genetic sequences 
responsible for particular illnesses and diseases, and in turn, work towards 
uncovering treatments and eventually cures.60  
D.  The Future of Genetic Research  
The HGP and the HapMap Project have greatly amplified genetic studies and 
research around the world, which has resulted in an increase of patent applications.61  
Within the United States alone, 3,000 to 5,000 patents on human genes have been 
issued, as well as around 47,000 patents for inventions related to genetic material.62  
While patenting is widely accepted around the world, “many countries limit the 
scope of gene patents as a way to minimize the negative impact on health care costs 
and on the free flow of information in research.”63  
The United States had the opportunity to limit the scope of gene patents when the 
government issued the AIA in September 2011; however, no measures to regulate 
gene patents were outlined in the new law.64 Gene patents should not be categorized 
as utility patents under the AIA. Instead gene patents should be categorized in a 
separate patent category, specifically designed to promote scientific research and 
collaboration.This in turn will advance scientific breakthroughs in health and 
science, resulting in positive diagnoses and treatments, thus saving millions of lives.   
III.  THE HISTORY OF THE U.S. PATENT SYSTEM AND THE EFFECT OF THE LEAHY-
SMITH AMERICA INVENTS ACT 
A.  Legislative History of the United States Patent System 
Under Article I, Section 8 of the United States Constitution, Congress has the 
power “to promote the Progress of Science and useful Arts, by securing for limited 
Times to Authors and Investors the exclusive Right to their respective Writings and 
                                                          
genetic variant involved in the disease may lie nearby.” International Consortium Launches 
Genetic Variation Mapping Project: HapMap will Help Identify Genetic Contributions to 
Common Diseases, supra note 18. Research has proven “that any two people are 99.9 percent 
identical at the genetic level, the 0.1 percent difference is important because it helps explain 
why one person is more susceptible to a specific disease – say diabetes – then someone who is 
less susceptible.” International Consortium Launches Genetic Variation Mapping Project: 
HapMap will Help Identify Genetic Contributions to Common Diseases, supra note 18.  
60 International Consortium Launches Genetic Variation Mapping Project: HapMap will 
Help Identify Genetic Contributions to Common Diseases, supra note 18. 
61 “A patent for an invention is the grant of a property right to the inventor, issued by the 
United States Patent and Trademark Office.” General Information Concerning Patents, 
UNITED STATES PATENT AND TRADEMARK OFFICE, http://www.uspto.gov/patents/resources/gen 
eral_info_concerning_patents.jsp (last visited Nov. 26, 2011).   
62 Robert Cook-Deegan, From Birth to Death and Bench to Clinic: The Hastings Center 
Bioethics Briefing Book for Journalists, Policy Makers, and Campaigns, 69, http://www.theha 
stingscenter.org/Publications/BriefingBook/Detail.aspx?id=2174 (last visited Oct. 25, 2011), 
cited in Zard, supra note 21.
63 Cook-Deegan, supra note 62.  
64 The Leahy-Smith America Invents Act, H.R. 1249, 120th Cong. (2011) (enacted), 
reprinted in www.uspto.gov/aia_implementation/bills-112hr1249enr.pdf .  
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Discoveries.”65 The first United States Patent Act was established in 1790.66 The 
statute remained unchanged until 1952.67  The Act of 1952 provided, “[w]hoever 
invents or discovers any new and useful process, machine, manufacture, or 
composition of matter, or any new and useful improvement thereof, may obtain a 
patent therefore, subject to the conditions and requirements of this title.”68 A 
patentable invention or discovery must be (1) novel, (2) nonobvious, (3) adequately 
described or enabled, and (4) claimed by the inventor in clear and definite terms.69  
The United States Patent and Trademark Office (“USPTO”)70 classifies patents into 
three categories: (1) utility patents, (2) design patents, and (3) plant patents.71  Gene 
patents are categorized under utility patents.72
                                                          
65 U.S. CONST. art. I, § 8, cited in Zard, supra note 21, at 490.  
66 1-1 Chisum on Patents §1.01 (LexisNexis 2011).  The Patent Act of 1790 “covered ‘any 
useful art, manufacture, engine, machine, or device, or any improvement therein.’” Id. The 
language was later changed “to read ‘any art, machine, manufacture, or composition of matter, 
or any new and useful improvement [therein].’” Id.  
67 Id. “[T]he Patent Act of 1952 changed the language from ‘art’ to mean ‘process,’ and 
defined ‘process’ as meaning ‘process, art or method.’ The 1952 Act also defined, particularly 
redundantly, ‘invention’ as ‘invention or discovery.’”  Id. 
68 35 U.S.C.S. § 101 (LexisNexis 2011), cited in Zard, supra note 21, at 487, 490. 
69 Patents, UNITED STATES PATENT AND TRADEMARK OFFICE, http://www.uspto.gov/inve 
ntors/patents.jsp#heading-5 (last visited Nov. 9, 2011).  
70 The United States Patent and Trademark Office (USPTO) is a government agency 
within the United States Department of Commerce. Zard, supra note 21. “[T]he USPTO 
fulfills the mandate of Article I, Section 8, Clause 8, of the Constitution that the Executive 
branch "promote the progress of science and the useful arts by securing for limited times to 
inventors the exclusive right to their respective discoveries." The USPTO: Who We Are, THE 
UNITED STATES PATENT AND TRADEMARK OFFICE, http://www.uspto.gov/about/index.jsp (last 
visited Jan. 19, 2012). Trademarks are registered by the USPTO based on the Commerce 
Clause. Id. Under the USPTO, the industry in America has flourished. Id.  “The strength and 
vitality of the U.S. economy depends directly on effective mechanisms that protect new ideas 
and investments in innovation and creativity.” Id. In addition to registering trademarks and 
patents, “[t]he USPTO advises the President of the United States, the Secretary of Commerce, 
and U.S. Government agencies on intellectual property (IP) policy, protection, and 
enforcement; and promotes the stronger and more effective IP protection around the world.”  
Id. The USPTO headquarters is located in Alexandria, Virginia. Id. The office is comprised of 
more than 8,900 employees including attorneys, analysts, engineers, scientists, and computer 
specialists.  Id.   
71 General Information Concerning Patents, supra note 61; see also Zard, supra note 21. 
72 General Information Concerning Patents, supra note 61. Utility patents are “[i]ssued 
for the invention of a new and useful process, machine, manufacture, or composition of 
matter, or a new and useful improvement thereof, it generally permits its owner to exclude 
others from making, using, or selling the invention for a period of up to twenty years from the 
date of patent application filing, subject to the payment of maintenance fees. Approximately 
90% of the patent documents issued by the PTO in recent years have been utility patents, also 
referred to as ‘patents for inventions.’” Types of Patents, UNITED STATES PATENT AND TRADE-
MARK OFFICE, http://www.uspto.gov/web/offices/ac/ido/oeip/taf/patdesc.htm (last visited Nov. 
26, 2011).  Design patents are issued for original, new, and ornamental design. Id. Design 
patents “permit[] its owner to exclude others from making, using, or selling the design for a 
period of fourteen years from the date of patent grant.” Id. Plant patents are issued for new, 
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In general, products from nature are not patentable; however, the USPTO permits 
genes, and even DNA, to be patentable subject matter.73 The USPTO defines “gene 
patents” to include “full-length protein encoding gene, a gene fragment, a regulatory 
region, a cDNA molecule, or a genomic region of unknown function.”74 For DNA to 
be a patentable subject matter, the USPTO requires that it be “isolated, purified, or 
modified to produce a unique form not found in nature” that has a specific 
application or use.75 Patent protection for utility patents lasts for twenty years from 
the date of the first application.76 To obtain a gene patent inventors are required to 
“(1) identify novel genetic sequences, (2) specify the sequence’s product, (3) specify 
how the product functions in nature (i.e. its use), and (4) enable one skilled in the 
field to use the sequence for that purpose.”77 While the USPTO appears to have a 
system in place to regulate gene patents, legal issues continue to exist that question 
whether genetic material is patentable subject matter within the scope of 35 U.S.C § 
101.78   
B.  The Common Law Approach to Gene Patents  
Much debate has arisen from legislative and judicial recognition of gene patents 
as patentable subject matter within the scope of 35 U.S.C. § 101. Arguments, both 
legal and ethical, concerning gene patents have been vocalized since 1980 with 
                                                          
distinct asexually reproduced plants “including cultivated sports, mutants, hybrids, and newly 
found seedlings, other than a tuber propagated plant or a plant found in an uncultivated state.”  
Id. Asexually reproduced plants reproduce via fragmentation or division. Asexual 
Reproduction, UCMP BERKLEY, http://www.ucmp.berkeley.edu/ glossary/gloss6/asexual.html 
(last visited Jan. 19, 2012). New plants grow by a “separation of parts [from] the original 
plant.” Id. In other words, “an offspring is created by the breakup of a single part of the plant.”  
Id. In essence, a plant clones itself through the process of asexual reproduction, which in some 
ecosystems is advantageous if genetic material through pollen reproduction is not readily 
available. Id. A plant patent is granted to cover the entire plant. General Information 
Concerning Patents, supra note 61. The plant patent term lasts twenty years from the date on 
which the application was filed in the U.S. General Information Concerning Patents, supra
note 61. Both utility and plant patents are protected for terms of twenty years, while the design 
patent is only protected for a fourteen-year term.  General Information Concerning Patents, 
supra note 61.   
73 Genetics and Patenting, HUMAN GENOME PROJECT INFORMATION, http://www.ornl.gov/s 
ci/techresources/Human_Genome/elsi/patents.shtml#1 (last visited Nov. 9, 2011).   
74  Zard, supra note 21 (citing Gregory C. Ellis, Emerging Biotechnologies Demand 
Defeat of Proposed Legislation that Attempts to Ban Gene Patents, 15 RICH. J.L. & TECH. 1, 7 
(2008)). 
75 Genetics and Patenting, supra note 73.  
76 Patents, supra note 69.  
77 Zard, supra note 21, at 492 (citing Genetics and Patenting, supra note 73); see also
Michele Westhoff, Gene Patents: Ethical Dilemmas and Possible Solutions, 20 HEALTH L. 1, 
3 (2008). 
78 See Diamond v. Chakrabarty, 447 U.S. 303 (1980). 
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Diamond v. Chakrabarty, and more recently in July, 2011 and again in August, 2012 
with the Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office.79   
1.  The Impact of Diamond v. Chakrabarty 
In Diamond v. Chakrabarty, the Supreme Court held that “[a] live, human-made 
micro-organism [was] patentable subject matter” pursuant to 35 U.S.C. § 101.80 In 
Chakrabarty, the defendant Chakrabarty, a microbiologist, filed an application to 
patent his “invention of ‘a bacterium from the genus pseudomonas.’”81 The “human-
made, genetically engineered bacterium” designed by Chakrabarty was “capable of 
breaking down multiple components of crude oil.”82 At that time, the discovery was 
believed to have made a substantial impact in the treatments used to clean up oil 
spills because no “naturally occurring bacteria” possesses such capabilities.83   
Chakrabarty applied for three different patent claims.84 The first claim was a 
process claim “for the method of producing the bacteria.”85 The second claim was 
“for an inoculum86 comprised of a carrier material floating on water,” and the 
invented bacteria.87 The third claim was solely for the invented bacteria.88 The patent 
                                                          
79 Chakrabarty, 447 U.S. at 303 (1980) (holding that a man-made microorganism was pat- 
entable under 35 U.S.C.S. § 101); Ass’n for Molecular Pathology v. U.S. Patent & Trademark 
Office, 2011 U.S. App. LEXIS 15649 (Fed. Cir. July 31, 2011) (holding that isolated DNA 
sequences were patentable subject matter); Ass’n for Molecular Pathology v. U.S. Patent & 
Trademark Office, 689 F.3d 1303 (2012).  
80 Chakrabarty, 447 U.S. 303 (1980).  
81 Id. at 305. The created bacteria contained “two stable energy generating plasmids, each 
said plasmids provid[ed] a separate hydrocarbon degradative pathway.” Id. “Plasmids are 
hereditary units physically separate from the chromosomes of the cell.” Id. at n.1.  
Chakrabarty discovered the plasmids control of the oil degradation abilities of certain bacteria 
through previous research with an associate. Id. Specifically, Chakrabarty and his associate 
found plasmids that were capable of degrading two components of oil, camphor and octane.  
Id. In the present case, “Chakrabarty discovered a process by which four different plasmids, 
capable of degrading four different oil components, could be transferred to and maintained 
stably in a single Pseudomonas bacterium, which itself has no capacity for degrading oil.”  Id.   
82 Id. at 305. 
83 Id. “At present, biological control of oil spills requires the use of a mixture of naturally 
occurring bacteria, each capable of degrading one component of the oil complex. In this way, 
oil is decomposed into simpler substances which can serve as food for aquatic life. However, 
for various reasons, only a portion of any such mixed culture survives to attack the oil spill.  
By breaking down multiple components of oil, Chakrabarty’s micro-organism promises more 
efficient and rapid oil-spill control.” Id. at n.2.  
84 Id. at 305. 
85 Id.
86 Inoculums are “cells used in an inoculation, such as cells to start a culture.” Inoculum, 
BIOLOGY-ONLINE, http://www.biology-online.org/dictionary/Inoculum (last visited Jan. 17, 
2012). In terms of microbiology, inoculation is “the act of introducing [a] microorganism or 
[a] suspension of microorganisms (e.g. bacteria) into a culture medium.  Id.   
87 Chakrabarty, 447 U.S. at 306 (1980).  
88 Id.  
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examiner approved the first two claims, however, the third claim was rejected for 
two reasons.89 First, the patent examiner argued that the “microorganism [was a] 
‘product[] of nature.’”90 Secondly, the patent examiner argued since the 
“microorganism [was a] ‘product[] of nature,’” it qualified as a living entity, and 
therefore was not patentable under 35 U.S.C. § 101.91 Chakrabarty appealed to the 
Patent Office Board of Appeals, which was later granted certiorari by the Supreme 
Court.92  
The main question before the Court was whether the microorganism could be 
classified as a “manufactured” entity or a “composition of matter’” within the scope 
of 35 U.S.C. § 101.93 The Court defined “manufacture” as “the production of articles 
for use from raw or prepared materials by giving to these materials new forms, 
qualities, properties, or combinations, whether by hand-labor or by machinery.”94  
“Composition of matter” was defined to include “all compositions of two or more 
substances and…all composite articles, whether they be the results of chemical 
union, or of mechanical mixture, or whether they be gases, fluids, powders, or 
solids.”95 The Court did not find “manufacture” and “composition of matter” to be 
ambiguous terms.96 Instead, the Court reasoned that Congress plainly used expansive 
language to provide a wide scope of patentable objects within the U.S. patent 
system.97 The Court argued the broad terms “fulfill[ed] the [C]onstitutional and 
statutory goal of promoting ‘the Progress of Science and the useful Arts’ with all the 
means for the social and economic benefits envisioned by [Thomas] Jefferson.”98  
                                                          
89 Id.  
90 Id. 
91 Id.  
92 Id. at 306-07. The Patent Office Board of Appeals found that 35 U.S.C. § 101 did not 
protect living entities, such as the one created by Chakrabarty. Id. at 306. The Court of 
Customs and Patent Appeals then reversed a prior decision it had made “in In re Bergy, 563 
F.2d 1031, 1038 (1977), which held that ‘the fact that microorganisms . . . are alive . . . [is] 
without legal significance’ for purposes of patent law.” Id. “Bergy involved a patent 
application for a pure culture of the micro-organism Streptomyces vellosus found to be useful 
in the production of lincomycin, an antibiotic.” Id. at n.4. The Supreme Court granted 
certiorari, and remanded Bergy “for further consideration in light of Parker v. Flook, 437 U.S. 
584.” Id. at 306. After, the Court of Customs and Patent Appeals vacated its decision in 
Chakrabarty and consolidated the case with Bergy for reconsideration, affirmed the earlier 
judgments. Id. The Supreme Court granted certiorari for both cases, however, Bergy was 
dismissed as moot, leaving only Chakrabarty.  Id. at 307.   
93 Id. at 307.   
94 Chakrabarty, 447 U.S. at 308 (citing American Fruit Growers, Inc. v. Brogdex Co., 283 
U.S. 1 (1931)).   
95 Chakrabarty, 447 U.S. at 308 (citing Shell Development Co. v. Watson, 149 F.Supp, 
279, 280 (D.C. 1957) (citing 1 A. Deller, Walker on Patents § 14, p. 55 (1st ed. 1937))). 
96 Chakrabarty, 447 U.S. at 315.  
97 Id. at 308.  
98 Id at 315. Thomas Jefferson was a major contributor to the Patent Act of 1793.  Id at 
308. Jefferson defined patentable subject matter as “any new and useful art, machine, 
manufacture, or composition of matter, or any new or useful improvement [thereof].”  
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While it appeared to the Court on the surface that Congress provided a wide 
scope in regards to the definition of “manufacture” and “composition of matter,” 
limitations exist that categorize certain entities as non-patentable objects.99  Abstract 
ideas, the laws of nature (i.e. gravity), and physical phenomena are three categories 
that cannot be patented.100 While an individual cannot patent the discovery of a new 
plant or the discovery of a new mineral on Earth, the Court found that the 
microorganism created by Chakrabarty could not be found in nature, and therefore, 
fit within the scope of “manufacture” and “composition of matter” under 35 U.S.C. § 
101 as patentable subject matter.101
The Supreme Court’s decision in Chakrabarty initiated a rush for gene patents 
within the U.S. patent system by widening the scope of patentable subject matter to 
allow all substances not found in nature to be patentable under 35 U.S.C. § 101.  
Since Chakrabarty, patents have been permitted for whole genes, segments of genes, 
and even fragments of DNA.102 While the USPTO has attempted to establish 
guidelines for gene patents since the Court’s holding in Chakrabarty, issues still 
arise today that question the very foundation of whether genetic information is 
patentable as seen in the Ass’n for Molecular Pathology v. U.S. Patent & Trademark 
Office.103
2.  The Ongoing Debate of the Ass’n for Molecular Pathology v. U.S. Patent & 
Trademark Office  
In the Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, the 
U.S. Court of Appeals for the Federal Circuit reversed the decision of the U.S. 
District Court for the Southern District of New York, holding that isolated DNA is 
patentable subject matter.104 Mutations in BRCA1 and BRCA2 genes have been 
linked to an increased risk of breast and ovarian cancer development in women.105  
Women in the United States have a twelve to thirteen percent chance of developing 
breast cancer within a lifetime.106 In the United States, women that have either a 
BRCA1 or BRCA2 mutation have a fifty to eighty percent chance of developing 
                                                          
Chakrabarty, 447 U.S. at 308 (citing Act of Feb. 21, 1793, § 1, 1 Stat. 319). The 1793 Act  
“embodied Jefferson’s philosophy that ‘ingenuity should receive a liberal encouragement.’” 
Chakrabarty, 447 U.S. at 308 (citing 5 WRITINGS OF THOMAS JEFFERSON 75-76 (Washington 
ed. 1871)).  
99 Chakrabarty, 447 U.S. at 309.  
100 Id.  
101 Id. at 309-10.  
102 Genetics and Patenting, supra note 73.   
103 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 2010-1406, 
2011 U.S. App. LEXIS 15649 at *54 (Fed. Cir. July 31, 2011).   
104 Id.  The non-patentability of the isolated DNA segments were not the only issues raised 
before the court.  Id. at *8. The plaintiffs “sought a declaration that fifteen claims from the 
seven patents assigned to Myriad [were] drawn to patent ineligible subject matter under 35 
U.S.C. § 101.”  Id.   
105 Id. at *17.   
106 Id.  
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breast cancer and a twenty to fifty percent chance of developing ovarian cancer.107  
Diagnostic testing provides women with information regarding their risk for 
developing hereditary breast and/or ovarian cancers, which in turn allows women the 
option to take preventative measures to avoid cancer development.108 Diagnostic 
results can also assist in developing proper chemotherapy treatments because some 
treatments are tailored to effectively treat BRCA1 and BRCA2 related cancers.109  
In the Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, the 
defendants, Myriad Genetics, Inc. (“Myriad”), discovered that BRCA1 and BRCA2 
mutations had a relationship with cancer development.110 Using DNA samples from 
families afflicted with inherited ovarian cancer and breast cancer, the researchers at 
Myriad were able to identify individual family members with a particular DNA 
sequence marker, which facilitated researchers to map the location of the BRCA1 
and BRCA2 genes within the human genome.111 Once the location of the two genes 
had been mapped, researchers isolated the exact nucleotide sequences, which 
allowed Myriad to provide BRCA1 and BRCA2 diagnostic testing for women with 
breast cancer and ovarian cancer.112   
Myriad filed its first patent application for the isolated BRCA1 DNA and the 
associated diagnostic methods in August 1994, and the patent, ‘472 patent, was 
issued in December 1997.113 Myriad filed its patent application for the isolated 
BRCA2 DNA and the associated diagnostic methods in December of 1995, and the 
patent, ‘492 patent, was issued in November 1998.114 The district court found that 
the isolated DNA molecules of BRCA1 and BRCA2, were non-patentable subject 
matter because the “isolated DNAs [were] not ‘markedly different’ from native 
                                                          
107 Id.
108 Id. 
109 Id. at *18.  
110 Id.  
111 Id.  
112 Id. 
113 Id.
114 Id. at *18-19. Even though Myriad had patents for both the isolated BRCA1 and 
BRCA1 DNA and subsequent diagnostic methods, Myriad was not the only entity to 
implement clinical testing with the two strands of DNA.  Id. at *19. In 1996, the University of 
Pennsylvania’s Genetic Diagnostic Laboratory, which was co-directed by some of the 
plaintiffs, began providing diagnostic services to women for BRCA1 and BRCA2. Id. The 
Genetic Diagnostic Laboratory was forced to stop providing services based on accusations by 
Myriad. Id. Around the same time, Myriad “initiated several other patent infringement suits 
against entities providing clinical BRCA testing. Id. at *22. Dr. Kazazian was one of the 
researchers at the Genetic Diagnostic Laboratory at the University of Pennsylvania. Id. at *19.  
Dr. Kazazian, like other researchers, believed that the patents held by Myriad should be found 
invalid so that he and other researchers could resume testing with BRCA. Id. at *23. After the 
plaintiffs filed suit, Myriad attempted to have the case dismissed alleging that the plaintiffs 
lacked standing. Id. The district court disagreed, and found that the plaintiffs had established 
standing with the “all circumstances” test.  Id. 
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DNAs,” and instead were properly categorized as “products of nature” within the 
exceptions of 35 U.S.C. § 101 as described in Chakrabarty.115   
To determine whether the BRCA1 and BRCA2 isolated DNA molecules were 
patentable subject matter, the court of appeals analyzed the Supreme Court’s 
decisions in Chakrabarty and Funk Brothers.116 Both cases involved patents 
regarding discovered bacteria, however, unlike Chakrabarty, the bacteria in Funk 
Brothers was non-patentable because the non-inhibition characteristic that was 
“newly discovered” was not “markedly different” from the bacteria found in 
nature.117 Therefore, the distinction between a product of nature and a patentable 
human-made discovery in correlation with 35 U.S.C. § 101 depends on “the claimed 
composition’s identity compared with what exists in nature.”118   
The court of appeals held that the BRCA1 and BRCA2 isolated sequences were 
patentable subject matter because the discovered sequences were different from the 
natural form, and, therefore, did not fall within the exceptions of 35 U.S.C. § 101.119  
The court came to this conclusion based on the science and techniques used by the 
Myriad researchers.120 Isolated DNA “is a free-standing portion of a native DNA 
molecule.”121 Isolated DNA has been synthesized to consist of a fraction of the 
naturally occurring DNA molecule.122 DNA that has been synthesized or cleaved 
from native DNA has a “distinctive chemical identity from that possessed by native 
DNA.”123 In their isolated states, BRCA1 and BRCA2 “are not the same molecules 
                                                          
115 Id. at *26. Myriad argued that the district court came to the incorrect conclusion by “(1) 
misreading Supreme Court precedent as excluding from patent eligibility all ‘products of 
nature’ unless ‘markedly different’ from naturally occurring ones; and (2) incorrectly focusing 
not on the differences between isolated and native DNAs, but on one similarity: their 
informational content.” Id. at *47-48. Myriad argued that “an isolated DNA molecule is patent 
eligible because it is, as claimed, ‘a nonnaturally occurring composition of matter’ with ‘a 
distinctive name, character and use.’” Id. at *48. Myriad outlined that “isolated DNA does not 
exist in nature, and isolated DNAs, unlike native DNAs [the natural form], can be used as 
primers and probes for diagnosing cancer.” Id. Myriad asserted that the “products of nature” 
exception not only wasn’t possible to apply because at some level every composition on Earth 
is comprised of natural materials, but that such a decision would go against the court’s 
precedents. Id. The plaintiffs responded by arguing that the Supreme Court’s precedents 
establish that “a product of nature is not patent eligible even if, as claimed, it has undergone 
some highly useful change from its natural form.” Id. Plaintiffs asserted that the isolated 
DNAs were not markedly different from its natural form, and in order to assert a composition 
as patent eligible, the composition must “have a distinctive name, character, and use, making 
it ‘markedly different’ from the natural product.” Id. at *49.   
116 Id.  at *51.   
117 Id. at *53.  
118 Id. at *54. 
119 Id.  
120 Id. at *56. 
121 Id. at *55. 
122 Id.  
123 Id. at *56. “[T]he BRCAI gene in its native state resides on chromosome 17, a DNA 
molecule of around eighty million nucleotides.” Id. at *55. “[The] BRCA2 in its native state is 
located on chromosome 13, a DNA of approximately 114 million nucleotides.  In contrast, 
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as DNA as it exists in the body.”124 In other words BRCA1 and BRCA2 are different 
from the DNA found in nature.125 The district court used a “categorical rule” that 
excluded isolated genes from patent eligibility, which the court of appeals 
rejected.126  
In addition to holding the BRCA1 and BRCA2 isolated sequences as patentable 
subject matter under 35 U.S.C. § 101 based on the test provided by Chakrabarty and 
Funk Brothers, the court of appeals also looked to the “longstanding practice” of the 
USPTO and the Supreme Court.127 The USPTO has issued patents for DNA 
molecules for almost thirty years beginning in the 1980s.128  It has been “estimated 
that the [US]PTO has issued 2,645 patents claiming ‘isolated DNA’” since 1980.129  
In addition, about 40,000 DNA-related patents have been issued since 2005, twenty 
percent of which were comprised of gene patents.130  Based on these statistics, it is 
no wonder that the court of appeals’ decision was applauded by the biotechnology 
industry.131 As stated by Gerald J. Flattmann Jr., a patent attorney for Paul Hastings 
in New York City, “It [the court of appeals] adhered to the policy the Patent Office 
has pursued since the early ‘80s, when the biotech industry was born.  Isolated gene 
patents are the cornerstones of the biotechnology industry.” 132
In his New York Times article Ruling Upholds Gene Patent In Cancer Test, 
Andrew Pollack commented that the Ass’n for Molecular Pathology might reach the 
Supreme Court for further ruling.133 The executive director of the Public Patent 
Foundation, Daniel B. Ravicher, who helped file the lawsuit, “called the decision a 
partial victory for the plaintiffs[,] [n]oting that one judge dissented on the gene 
patents.”134 Ravicher also commented “the plaintiffs were considering either asking 
                                                          
isolated BRCA1 and BRCA2, with introns, each consist of just 80,000 or so nucleotides.  And 
without introns, BRCA2 shrinks to just 10,200 or so nucleotides and BRCA1 to just around 
5,000 nucleotides.” Id. An intron is “[p]art of a gene that is initially transcribed into the 
primary RNA transcript but then removed from it when the exon sequences on either side of it 
are spliced together.”  Intron, MEDICINENET.COM, http://www.medterms.com/script/main/art.a 
sp?articlekey=4026 (last visited Jan. 18, 2012). An intron is also known as an intervening 
sequence.  Id.  
124 Ass’n Molecular Pathology, 2011 U.S. App. LEXIS 15649 at *56. 
125 Id.
126 Id. at *60. 
127 Id. at *64. 
128 Id. at *65. 
129 Id.
130 Id.  
131 Andrew Pollack, Ruling Upholds Gene Patent in Cancer Test, N.Y. TIMES, July 29, 
2011, http://www.nytimes.com/2011/07/30/business/gene-patent-in-cancer-test-upheld-by-app 
eals-panel.html?_r=1 (last visited Jan. 18, 2012). 
132 Id.  
133 Id.  
134 Id.  
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the entire appellate court to rehear the gene patenting aspects of the case or 
appealing to the Supreme Court.”135   
A petition of certiorari was filed from the July 29, 2011 court of appeals opinion, 
in which the Supreme Court of the United States granted the petition, vacated the 
decision, and remanded the case back to the court of appeals to be reconsidered in 
the light of the Supreme Court’s decision in Mayo Collaborative Services v. 
Prometheus Inc. (“Mayo”).136 The Supreme Court’s decision in Mayo “tightened 
rules on medical-testing patents.”137 Specifically, the court “invalidated a pair of 
‘method’ patents that claimed a process for setting dosages.”138 In the remanded 
appeal, the court of appeals made a decision, which decided the issues on the 
original appeal and evaluated the effect of Mayo on the original issues.139 On 
remand, the court of appeals reversed the district court’s holding “that Myriad’s 
composition claims to ‘isolated’ DNA molecules cover patent-ineligible products of 
nature under § 101 because each of the claimed molecules represents a nonnaturally 
occurring composition of matter.”140 Shortly after the court of appeals remanded 
decision, the Supreme Court granted certiorari to establish whether human genes are 
patentable subject matter.141     
While Chakrabarty and the Ass’n for Molecular Pathology establish the 
constitutional concerns regarding gene patents that the judicial system has so far 
overturned, society has become increasingly split in its opinions of whether gene 
patents should be permissible within the U.S. patent system. 
                                                          
135 Id.  
136 Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 689 F.3d 1303, 
1308 (Fed. Cir. Aug. 16, 2012).   
137 Brent Kendall, Court to Decide Whether Genes Can Be Patented, WALL ST. J., July 20, 
2012, at A3.  
138 Id. “Judge Kimberly Moore, who penned a concurring opinion for the Federal Circuit 
last year, wrote that the Myriad patents ‘raise substantial moral and ethical issues related to 
awarding a property right to isolated portions of human DNA-the very thing that makes us 
humans, and not chimpanzees.’ But she also said that the U.S. Patent and Trademark Office 
has allowed patents on the DNA sequences for decades and that disturbing the industries long-
held expectations risked impeding innovation.” Id.   
139 Ass’n Molecular Pathology, 689 F.3d at 1308. 
140 Id. at 1308-09. The court “also reversed the district court’s decision that Myriad’s 
method claim to screening potential cancer therapeutics via changes in cell growth rates of 
transformed cells is directed to a patent-ineligible scientific principle.” Id. Lastly, the court 
affirmed the district court’s decision that the claims that “comparing” and “analyzing” 
procedures for DNA sequences were patent ineligible because there were no transformative 
steps.  Id.   
141 Id. at 1308. On June 13, 2013, the Supreme Court of the United States unanimously 
established that human genes may not be patented.  Adam Liptak, Justices, 9-0, Bar Patenting 
Human Genes, N.Y. TIMES, June 13, 2013, http://www.nytimes.com/2013/06/14/us/supreme-
court-rules-human-genes-may-not-be-patented.html?_r=0 (last visited June 23, 2013). Justice 
Clarence Thomas wrote for the court that “‘Myriad did not create anything…[t]o be sure, it 
found an important and useful gene, but separating the gene from its surrounding genetic 
material is not an act of invention.’”  Id.  This ruling “drew a sharp distinction between DNA 
that appears in nature and synthetic DNA created in the laboratory.” Id. 
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3.  Society’s Split on Gene Patents  
Since the 1980s with the Supreme Court’s holding in Chakrabarty, a split has 
developed within society’s view regarding the patentability of genetic material. 
Proponents argue that gene patents (1) reward researchers for their work and supply 
monetary rewards to further their research, (2) “provide a monopoly to [] 
inventor[s]” in turn “prohibiting competitors from making, using, or selling [] 
patented discover[ies],” (3) prevent “wasteful duplications,” (4) force science to 
reach “into new, unexplored areas,” and (5) reduce innovative secrecy and promote 
communication between researchers.142 Opponents argue that gene patents (1) 
impede on scientific research, (2) allow researchers to patent a part of nature, and (3) 
allow monopolies.143 The themes argued by both sides of the debate can be 
categorized into three sections: (1) the issues surrounding the creation of 
monopolies, (2) the issues concerning the affects on scientific research, and (3) the 
issues concerning patenting a part of “nature.”  
i.  Monopolies   
Proponents of patenting genetic material argue that gene patents allow 
researchers to monopolize their discoveries, which provides monetary and property 
rewards.144 “Patents facilitate genetic research by encouraging investment in what 
would otherwise be a risky financial investment.”145 The biotechnology industry, as 
a whole, is a strong proponent for gene patents because a large portion of profit 
comes from “intellectual and financial investments,” which in turn facilitate 
research.146 Individuals challenging gene patents maintain that while monopolies 
may be an asset to large biotechnological corporations, monopolies hurt smaller 
corporations.147 Proponents for gene patents, however, disagree and argue that small 
biotechnological corporations gain the same benefits as larger biotechnological 
corporations.148 Regardless of size, if gene patents are barred, corporations that do 
not have the sources to fund research will lose the ability to attract investors, 
ultimately resulting in delays in research or completely preventing research from 
occurring.149   
While monopolies created by gene patents arguably assist in funding future 
research, opponents argue that monopolies raise the cost of diagnostic testing that 
could be reduced if biotechnological companies did not hold monopolies over their 
patents.150 For example, Myriad Genetics, Inc. holds the patents for both BRCA1 
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and BRCA2 genes.151 Myriad, being the only entity permitted to use the genes, 
charges more than $3,000 for its diagnostic test to determine whether an individual is 
at risk for breast or ovarian cancer.152 While this is a strong argument against 
monopolies created by gene patents, in essence, all patents create a monopoly due to 
the basic concepts patents are based upon.153  
                                                          
151 Pollack, supra note 131.
152 Pollack, supra note 131. While Myriad Genetics retained its monopolies over the 
BRCA1 and BRCA2 genes, it is only a matter of time before Myriad has challenges to face 
again. Andrew Pollack, Despite Gene Patent Victory, Myriad Genetics Faces Challenges, THE 
N.Y. TIMES (Aug. 24, 2011), http://www.nytimes.com/2011/08/25/ business/despite-gene-
patent-victory-myriad-genetics-faces-challenges.html?_r=1&pagewanted=all. Experts believe 
that the expensive testing will become incompetent and will be “outmoded, complete, and too 
costly” as technological breakthroughs continue to occur. Id. Mary-Claire King, a professor of 
genome sciences and medicine at the University of Washington argues that “Science has 
moved beyond what these folks do. It’s not good for the science and it’s not good for the 
patients and their clinicians if they cannot have the most complete, up-to-date information.”  
Id. The new techniques used with DNA sequences are faster and cheaper than the technology 
that Myriad developed in the 1990s. Id. Soon, for the same price that Myriad chargers for just 
two genes, individuals will be able to have their entire genome sequence mapped -- about 
22,000 genes. Id. Myriad executives counter that the company is preparing for the 
technological changes. Id. Executives also point out that the “company’s patent protection 
should last until at least 2018,” which will give the company the opportunity to adopt and 
diversify the latest technology. Id. The company announced plans that it intends to rely less on 
patents, and instead rely on trade secrets. Id. Myriad has done the most in terms of testing with 
BRCA1 and BRCA2 genes, and it is more than likely that Myriad knows “which of the 
thousands of possible mutations in the two genes actually raise the risk of cancer.” Id.  
“Myriad used to share such information with a public database maintained by the National 
Institutes of Health, and it cooperated with academic scientists trying to analyze the mutations 
[; however,] a few years ago, the company quietly stopped contributing and cooperating, in 
favor of building its own database.” Id. In 2006, Myriad developed a supplemental test, 
known as the Comprehensive BRAC Analysis, that corrected issues from its previous test.  Id.  
The supplemental test cost $700, but insurers do not cover the cost, leaving many women 
without the opportunity to obtain the test. Id. “More than 200 doctors, genetic counselors and 
other health care professionals have signed an open letter to Myriad urging it to incorporate 
the supplemental testing into the main test.” Id. For example:   
Kathleen Maxian says that if that had been done earlier, she might not be fighting for 
her life against ovarian cancer. Her sister developed breast cancer at age 40 about five 
years ago, but tested negative for mutations on Myriad’s main test. She was not 
offered the supplemental test. Two years ago, Ms. Maxian developed ovarian cancer.  
It turned out that both she and her sister had genetic alterations that were detectable 
only by the supplemental test. ‘If my sister had had that test and had gotten a positive 
result, I would have gone to a genetic counselor and have been tested,’ said Ms. 
Maxian, who is 49 and lives in Pendleton, N.Y., near Buffalo. She would then have 
had the option of having her ovaries removed to avoid getting ovarian cancer. ‘I don’t 
want to see this happen to anyone else,’ she said. ‘Women should have this test.’  
Id.
153 Gene Quinn, Patent Misuse, Exploring the Basics, IPWATCHDOG (March 11, 2013), 
http://www.ipwatchdog.com/2011/11/18/patent-misuse-exploring-the-basics/id=20460/  
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In Kewanne Oil Co. v. Bicron Corp., the Supreme Court justified the purpose of 
patents “to provide incentives for inventiveness and research efforts.”154 It was the 
intentions of the Framers’ to grant temporary exclusive rights to researchers for their 
discoveries to further promote research and development and allow rewards for 
researchers.155 Monopolies are inevitable with the use of not only gene patents but 
patents in general. Monopoly can be defined as an “exclusive ownership through 
legal privilege.”156 A patent as defined by Merriam-Webster, is “a: a writing securing 
for a term of years the exclusive right to make, use, or sell an invention [or] b: the 
monopoly or right so granted.”157 By granting an individual the exclusive right over 
their discovery, a monopoly is automatically created. Therefore if opponents to gene 
patents wish to eliminate the monopolies created by patents in entirety, the concept 
of patents would have to be eliminated, which goes against the intentions of the 
Framers’.   
ii.  The Effects on Science and Genetic Research   
Proponents of gene patents argue that scientific research and discoveries are 
amplified with the use of gene patents, while opponents argue that gene patents place 
a significant hold and block on the collaborative basis for which scientific research 
occurs.158 Both sides of the debate are correct in their analysis; however, both 
aspects are needed to further promote scientific research and scientific 
breakthroughs.  This concept will be further analyzed in Part IV of this Note.  
iii.  Patenting an Aspect of Nature  
Whether genetic material can be categorized as patentable subject matter in 
connection with 35 U.S.C. § 101, has been a topic of much debate since the 1980s.  
The Ass’n for Molecular Pathology is the most recent case that demonstrates the 
judicial stance on gene patents as patentable subject matter within scope of 35 
U.S.C. § 101.159 With both the courts and the USPTO support of gene patents for 
almost thirty years, it is unlikely that the norm will change.160 In its recent grant of 
certiorari in the Ass’n for Molecular Pathology, the Supreme Court will likely affirm 
the court of appeals decision and permit isolated DNA sequences as patentable 
                                                          
154 Zard, supra note 21 (citing Kewanee Oil Co. v. Bicron Corp., 416 U.S. 470, 480-81 
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159 See Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 689 F.3d 
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subject matter as it has been the protocol since Chakrabarty.161 Changing the 
standard by which scientists and the biomedical industry have come accustomed to 
since 1980 and the holding in Chakrabarty, a loss for Myriad could significantly hurt 
the biomedical industry and scientific progress.162
 The purpose of this Note is not to analyze whether genetic material is patentable 
subject matter under 35 U.S.C. § 101. This Note is written following the latest 
judicial decision in Ass’n for Molecular Pathology, in addition to the historical 
stance the USPTO and the courts have followed, in finding that genetic material is 
patentable subject matter under 35 U.S.C. § 101. The remainder of this Note 
addresses whether the new Leahy-Smith America Invents Act (“AIA”) implements 
the expressed societal concerns surrounding gene patent regulations, and examines 
changes that need to be implemented to promote scientific research and collaboration 
that will foster more timely results in diagnostic technologies and treatments. 
IV.  LEAHY-SMITH AMERICA INVENTS ACT (“AIA”) 
The AIA is the first major reform to the United States patent law system since 
1952.163 The AIA, while narrow in scope, keeps the basic structure of the U.S. patent 
system by implementing numerous changes to promote efficiency and structure.164   
While the AIA does promote new changes and advances in the U.S. patent system, 
the AIA does not address the concerns established by critics of gene patents that 
grew from the Patent Act of 1952 and the recent explosion in genetic research.165
Before criticizing the AIA for neglecting to implement procedures and regulations 
specifically designed for gene patents, a thorough overview on the new legislation 
must be provided.   
The AIA harmonizes the U.S. patent system with other patent systems 
established in Europe and other countries by implementing a first-inventor-to-file 
system (“FITF”).166 The AIA also addresses issues that have negatively impacted the 
U.S. patent system.  The AIA amends the “joinder standard for joining defendants in 
a patent infringement action and eliminat[es] qui tam false marking actions 
entirely.167 In addition to implementing the FITF system, the AIA also promotes 
                                                          
161 Kendall, Supra note 137. 
162 Kendall, Supra note 137.  
163 Erick Bensen, Erick E. Bensen on the America Invents Act, 2011 EMERGING ISSUES
5900 (LexisNexis 2011).  
164 The Leahy-Smith America Invents Act, H.R. 1249, 120th Cong. (2011) (enacted), 
reprinted in www.uspto.gov/aia_implementation/bills-112hr1249enr.pdf .  
165 Id.  
166 1 PAT. L. FUNDAMENTALS § 1:37 (West 2013); see John E. Schneider, Leahy-Smith 
America Invents Act – Patent Reform 2011 is Finally Here, 2011 EMERGING ISSUES 5929 
(LexisNexis 2012).  
167 John E. Schneider, supra note 166. Prior to the implementation of the AIA, “any 
individual could bring a qui tam action on products that [were] mismarked as covered by a 
patent,” under 35 U.S.C. § 292(a). Zahra Hayat, Esq. at. el., How the America Invents Act will 
change patent litigation, WESTLAW JOURNAL INTELLECTUAL PROPERTY, Nov. 18, 2011, 
http://newsandinsight.thomsonreuters.com/Legal/Insight/2011/11_-_November/How_the_Am 
erica_Invents_Act_will_change_patent_litigation/ (last visited Jan. 19, 2012). The statute 
allotted for fines of $500 “per offense” which in the end could add up to millions of dollars if 
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faster patent processing, implements a new derivation proceeding, and revamps the 
post-patent review proceedings.168   
A.  Patent Processing    
1.  First-Inventor-to-File  
A major change the AIA makes to the U.S. patent system is the conversion from 
a first-to-invent system to a first-inventor-to-file (“FITF”) system.169 Changing the 
U.S. patent system to the FITF system harmonizes the U.S. patent system with the 
European patent system, giving American inventors more protection abroad by 
making the patent process more efficient, predictable, and in accords with foreign 
guidelines.170 The adoption of the FITF system will be officially implemented 
eighteen months from the date President Obama signed the AIA into law.171 During 
this eighteen-month period, the AIA calls for two studies to be performed.172 The 
first study is designed to look into the effect the FITF system will have on small 
businesses, while the second study determines whether the U.S. should implement a 
“prior user rights.”173 The delay will allow Congress to assess the findings of the two 
studies to determine if and what change need to be made to the FITF system.174   
i.  Changes Made by the FITF System 
The AIA changes the language of the old first-to-invent system to the FITF 
system by amending the language to state “that a person shall be entitled to a patent 
unless it was made available to the public, sold, or offered for sale anywhere in the 
world, or patented or described in a publication before the effective filing date of the 
claimed invention.”175 With the new system, patents and published patent 
applications become “prior art” on the “effective filing date” of the patent or patent 
application.176  “Effective filing date” is defined by the AIA “as the actual filing date 
of an application or the filing date of the earliest application for which the patent or 
                                                          
a product was popular among the public. Id. Under the new regulations implemented by the 
AIA, only the United States government will be able to sue for damages for false marking.  Id.  
“Private parties will be entitled only to compensatory damages based on ‘competitive injury 
flowing from the false marking.”  Id. This new legislation will apply to pending cases, as well 
as on cases that were commenced on or after the enactment of the AIA. Id. It is likely, that 
because of these new regulations, that false marking cases will become rare in the future.  Id.   
168 John E. Schneider, supra note 166.   
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reprinted in www.uspto.gov/aia_implementation/bills-112hr1249enr.pdf 
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174 John E. Schneider, supra note 166.  
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application is entitled for that invention.”177 The implementation of a FITF system 
will end the need for expensive discovery and litigation over priority dates because 
inventors will now be able to establish priority dates by filing an inexpensive, simple 
application.178   
ii.  Exceptions to the FITF System  
The FITF system has two main exceptions.179 The first exception entitles 
inventors “to a one year grace period for disclosures made by the inventor or by one 
who obtained the disclosed information from the inventor.”180 The AIA, however, 
does not define the term “disclosure.”181 The definition will likely be left to the 
courts to determine, as it will more than likely be a topic of early-litigated actions.182  
The second exception excludes “narrow categories of patents and published 
applications that encompass [an] inventor’s own work.”183 These narrow categories 
incorporate patents and applications that release information acquired by the 
inventor, information that was described in a publication by the inventor, or 
information that was owned or assigned to a common owner.184 An example of work 
that may fall within the second exception would be information developed from a 
joint research agreement between two inventors.185 In addition to changing the patent 
system to FITF system, the AIA also changes the rights of third parties.  
2.  Submissions by Third Parties  
Before the AIA, under the former patent legislation, third parties had limited 
input with the patent application process.186 Now, under the AIA, “any third party 
may submit prior art for consideration and inclusion in the record of a patent 
application.”187 Prior art can be defined to be “any patent, published patent 
application, or other printed publication of potential relevance to the examination of 
the application.”188 A submission of prior art by a third party must be made in 
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writing within six months of the application publication.189  The submission “must 
set forth a concise description of the asserted relevance of each submitted 
document.”190 Along with the rights of third parties being recognized, the AIA also 
changed the means by which an applicant inventor can make an oath.   
3.  Inventors Oath 
Pursuant to the prior patent legislation, “applicants were required to provide an 
oath or declaration of each applicant inventor stating that the applicant ‘believed 
himself to be the original and first inventor of the process, machine, manufacture, or 
composition of matter, or improvement thereof for which he solicits a patent.’”191  
Now, under the AIA, a modification in the provision has been amended for applicant 
inventors that are “deceased, under legal capacity, can not be found after diligent 
effort, or [are] under obligation to assign the invention but [have] refused to make 
oath or declaration.”192 In such circumstances, the AIA has given the option for an 
applicant inventor to substitute a statement in lieu of an inventor oath or 
declaration.193 While making some positive changes, the AIA has also prohibited a 
few means of former patentable subject matter.  
4.  Tax Strategies with Patent Applications  
Under former patent legislation, individuals could obtain patents for “tax 
strategies for lowering or reducing tax liability.”194 Under the AIA, such patent 
applications are prohibited, “by defining such an invention, including any strategy 
for reducing, avoiding, or deferring tax liability…as deemed insufficient to 
differentiate a claimed invention from the prior art.”195  
5.  Human Organisms  
Under former U.S. patent legislation, it was the USPTO’s policy to reject patent 
applications or claims regarding human organisms.196 The AIA has codified this 
policy, formerly known as MPEP § 2105, by establishing that “human organisms 
[were] not patentable subject matter.”197 An organism is “[a]n individual living thing 
that can react to stimuli, reproduce, grow, and maintain homeostasis.”198 Pursuant to 









197 Id. (Pursuant to MPEP § 2105, “[i]f the broadest reasonable interpretation of the 
claimed invention as a whole encompasses a human being, then a rejection under 35 U.S.C. § 
101 must be made indicating that the claimed invention is directed to nonstatutory subject 
matter.”)    
198 Organism, BIOLOGY ONLINE, http://www.biology-online.org/dictionary/Organism (last 
visited Feb. 20, 2013).  
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the definition of organism, the prohibition on human organism patents by the AIA 
does not include gene patents because (1) genes are merely a sequence of nucleotides 
(a segment of DNA) found on a chromosome that is part of an organism, and (2) 
genes cannot react to stimuli, grow, or reproduce.199 Thus, gene patents are still 
untouched by the prohibitions established by the AIA.  
6.  Prioritized Examination  
Under the AIA, the USPTO provides a “prioritized examination” option, in 
which individuals can purchase “prioritized examination” upon filing a patent 
application.200 An application with “prioritized examination” gives an application 
“special status” in order for the application to be advanced through the USPTO’s 
examination process.201  This “special status” allows applications to be processed at 
a faster rate so that a final disposition can be granted within twelve months of the 
priority examination date.202 Status can be granted through one of the following: 
• “[m]ailing of a notice of allowance;”203
• “mailing of a final Office action;”204
• “filing of a notice of appeal;”205
• “completion of examination as defined in 37 C.F.R. 41.102;”206
• “filing of a request for continued examination; or”207
• “abandonment of the application”208
In addition to a fee for prioritized examination, applicants still must pay the 
ordinary filing fee, search fee, and other miscellaneous fees.209  One of the 
goals of the AIA is to implement an overall faster patent process.   
7.  Faster Patent Processing  
The AIA has a twelve-month guarantee for patent processing, which significantly 
decreases patent processing from an average of three years, and thus aids in the 
reduction of the present patent backlog.210 Currently, the backlog has been reduced 
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to 680,000 from 750,000 despite a 4% increase in filings.211 Horacio Gutierrez, 
Microsoft’s deputy general counsel for intellectual property and licensing, 
commented that the changes the AIA makes “‘will ensure that innovators in our 
troubled economy can benefit from a predictable and rational patent system, with 
new tools to eliminate patents that should not have been issued and to speed the 
processing of patents that should be issued.’”212 In connection with implementing the 
FITF system and decreasing the patent processing time period, the AIA also 
establishes a new protective proceeding for inventors.    
8.  Derivation Proceedings 
The AIA’s implementation of the derivation proceedings eliminates the U.S. 
patent systems’ previously used process of interferences.213  Derivation proceedings 
determine whether a patented invention was derived from the work of another 
patented invention or patent application.214 These proceedings can be heard in two 
different systems depending on the particular issues.215  If the conflict arises between 
two different patents, the hearing will proceed in district court.216 If the conflict 
arises between a patent and an application or two different applications, the 
proceedings will occur at the USPTO in front of the Patent Trial and Appeal 
Board.217  In addition to providing changes with filing, processing and initial legal 
proceedings, the AIA also implements new plans for post-patent proceedings.218   
B.  Post-Patent Proceedings and Review  
The AIA brings numerous changes to the U.S. patent systems standard of review 
for granted patents.219 While the AIA retains reissue and Ex Parte Reexamination 
proceedings enacted from previous patent acts, it replaces the Inter Partes 
Reexaminations with the Inter Partes Review, and adds two additional proceedings, 
the Post Grant Review and the Supplemental Examination proceedings, to the U.S. 
patent system.220  
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1.  Inter Partes Review  
Congress introduced the inter partes reexamination principle in the 
Reexamination Act in 1980.221 The purpose of the inter partes reexamination 
principle was to “‘strengthen investor confidence in the certainty of patent rights by 
establishing a system of administrative reexamination of doubtful patents.’”222 While 
the new inter partes review upholds the baseline of the previous process, the new 
proceeding changes when a petition for review can be filed.223 Under the AIA, a 
petition for review can be filed nine months after a patent has been granted or if a 
post grant review has commenced, a petition can be filed after a decision has been 
reached.224 The inter partes review also implements a new standard of review, which 
analyzes whether a reasonable likelihood exists that the petitioner will prevail in 
respect to one of the challenged claims.225 In addition, the AIA also seeks to speed 
up the inter partes review process, an underlying theme seen throughout the AIA.226  
Similar to the inter partes review, the post grant review system implemented by the 
AIA seeks to challenge the validity of patents.227   
2.  Post Grant Review  
The AIA created a new proceeding, post grant review (“PGR”), “where third 
parties are able to challenge the validity and scope of an issued patent.”228 Prior to 
the AIA, individuals were limited to challenge patents solely based on obviousness 
and novelty, and based upon “prior patents or printed publications.”229  Under PGR, 
an individual can challenge a patent on any ground of patentability and is not limited 
to prior art patents and printed publications.230 PGR can be implemented in two 
circumstances.231 First, PGR can be implemented if the information in the petition 
demonstrates that one of the challenged claims is more likely than not patentable.232  
Secondly, PGR can be implemented if the petition raises a novel or unsettled legal 
question that is important to other similar patents and patent applications.233 A PGR 
must be filed within nine months of the issuance of the patent or “issuance of a 
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broadening reissue.”234 A petitioner must chose between challenging a patent with 
either the USPTO or the courts.235 The AIA does not establish specific rules 
concerning the “rules of conduct” for the PGR; instead the AIA left the USPTO the 
responsibility of developing the rules.236 In addition to creating the PGR 
proceedings, the AIA also establishes Supplemental Examination proceedings.  
3.  Supplemental Examination  
Supplemental examination allows a patent owner the ability to address any 
validity issues that may have been uncovered after the patent had been granted.237  
This process begins after a patent owner files a petition with the USPTO “raising at 
least one new substantial question of patentability.”238 If the USPTO finds that the 
owner of a patent has raised a substantial question of patentability, then the patent 
will be examined under the procedures for ex parte reexamination.239 Ex parte 
reexamination provides patent owners and third parties the ability to request the 
USPTO to reconsider patents that are based on pre-existing technology that was not 
initially reviewed.240 The USPTO only reexamines patents that propose a new 
substantial question that needs to be reviewed.241 While making substantial changes 
and improvements to the U.S. patent system with the implementation of the FITF 
system, faster patent processing, the creation of derivation proceedings, and the 
reworking of the post patent processing, the AIA does not address or implement new 
guidelines specifically designed to regulate gene patents.   
C.  Litigation  
1.  Defenses to Infringement Cases 
Under the AIA, the “prior use” defense, which originally was only permitted for 
business method patent cases, is expanded as a defense for patent infringement for 
all patent types.242 The prior use defense prohibits patent infringement243 claims 
against individuals that show that (1) “they acted in good faith;” (2) “they actually 
reduced the subject matter of a patented invention to practice at least one year before 
the patentee filed its patent application;” and (3) “they commercially used that 
subject matter before the patentee filed its patent application.”244   
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2.  Joinder of Parties in Infringement Litigation Cases 
While expanding the scope of infringement cases, the AIA limits the number of 
joinder of parties in infringements cases.245 A plaintiff that is related to the parties in 
a single suit can only join lawsuits filed on or after the date of enactment.246 This 
limit is implemented to require separate lawsuits to allow defendants to have an 
easier means to seek venue transfer.247   
3.  Venue  
Under the AIA, venue for patent litigation involving the USPTO has been 
changed.248  Previously, patent litigation cases were filed in the U.S. District Court 
for the District of Columbia.249  Now, pursuant to the AIA, cases are to be filed in 
the U.S. District Court of the Eastern District of Virginia,250 specifically for cases 
filed under the following sections: 
• “Section 32 related to disciplinary proceedings against patent 
practitioners;”251
• “Section 145 related to civil actions to obtain a patent;”252
• “Section 154(b) related to patent term adjustment;”253 and 
• “Section 146 related to civil actions in interference cases actions 
against a foreign patent owner”254
In addition to changing venue for particular patent cases, the AIA also narrowed 
the scope of false marketing cases.   
4.  Advice of Counsel Defense  
Under the AIA, if a defendant in a patent infringement lawsuit fails to obtain 
advice of legal counsel, such failure “cannot be used to prove that the defendant 
willfully infringed the patent” at issue.255  
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5.  False Marketing Cases  
Prior to the AIA, any person could sue for false marketing under the false 
marketing statute qui tam provision.256 The AIA eliminates false marketing lawsuits 
for “any person,” except for cases filed by a competitor who can prove competitive 
injury or the U.S. government.257 This provision of the AIA applies retroactively 
from the date of enactment.258   
D.  The AIA’s Answers for Gene Patents and Scientific Research  
While the AIA implemented numerous new initiatives and protocols to revamp 
the U.S. patent system, gene patents were not included in the overall master plan.  
On the same day that the AIA was officially signed into law by President Obama, 
plans were announced for the development of a national bioeconomy blueprint by 
January 2012.259 The Obama Administration announced a plan to create a 
bioeconomy blueprint that will detail “[a]dministration-wide steps to harness 
biological research innovations to address national challenges in health, food, 
energy, and the environment.”260  
Biological research, specifically genetic research, plays a significant role in the 
United States’ economy and the well being of Americans.261 To ensure that this trend 
continues, the bioeconomic blueprint is intended to “focus on reforms to speed up 
commercialization and open new markets, strategic [research and development] 
investments to accelerate innovation, regulatory reforms to reduce unnecessary 
burden on innovators, enhanced workforce training to develop the next generation of 
scientists and engineers, and the development of public-private partnerships.”262   
In addition to the bioeconomic blueprint, the National Institute of Health (“NIH”) 
will be launching a program aimed to assist biotechnical entrepreneurs.263 The NIH 
plans to establish a National Center for Advancing Translational Sciences 
(“NCATS”) that will identify barriers in the way of scientific progress, such as 
financial barriers.264 Though it appears that the Obama Administration, through the 
AIA, is taking initiative to promote genetic research and to foster scientific progress, 
in reality, separate regulations in conjunction with the AIA are required to establish 
specific guidelines for gene patents to promote scientific research and collaboration, 
which will ultimately result in faster diagnostic and health discoveries.   
Overall, the AIA implements positive changes to the U.S. patent system; 
however, the AIA failed to establish guidelines specifically designed to regulate 
gene patents. Gene patents have been a topic of controversy since the Supreme 
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Court’s decision in Chakrabarty.265 Numerous concerns have been raised through 
case law and scholarly articles outlining the issues that need to be addressed by 
legislation.266 Instead of correcting the problem, the AIA has remained silent. The 
answer is not to conduct more studies and launch separate programs in conjunction 
with the AIA to develop “blueprints” for genetic and scientific research as suggested 
by the Obama Administration.  The time for action is now.  Genetic research can and 
will lead to the discovery of new diagnostic treatments and cures; cures that could 
have saved Kathy Hopkins and Greg Knittel. The answers that genetic research can 
provide society are eminent, and the discoveries genetic research can provide to 
healthcare services is potentially world changing. Gene patents should be 
categorized in a separate patent category within the AIA, under regulations 
specifically designed to promote scientific research and collaboration that will in 
turn foster faster results for diagnostic technologies and treatments. 
V.  THE IMPACTS OF GENE PATENTS ON SCIENTIFIC RESEARCH AND THE NEED FOR 
LEGISLATIVE GUIDELINES
The U.S. patent system needs to be adapted for the rapidly changing field of 
genetics by implementing new regulations for gene patents specifically designed to 
promote scientific research and collaboration.267 To adapt for the rapidly changing 
field of genetics, the AIA, and thus the U.S. patent system, should be amended to 
implement the following regulations specifically geared for gene patents: 
(1) establish a new patent category specifically engineered for gene 
patents;  
(2) reduce the period of gene patent protection to promote collaboration 
among researchers and foster faster research results;  
(3) require individuals with patents to share their research on the 
GenBank database to further promote collaboration and render faster 
results; and lastly,  
(4) implement patent pooling as another mechanism to promote 
collaboration and increase discovery rates.   
Each proposal will be discussed in detail below.   
A.  The Creation of a New Patent Category: Gene Patents  
Instead of categorizing and regulating gene patents under the same guidelines as 
utility patents, separate legislation should be implemented to categorize and regulate 
gene patents as separate entities. Currently, the patent system only identifies three 
categories of patents: (1) utility patents, (2) design patents, and (3) plant patents.268
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Gene patents are a subcategory under utility patents.269 Plant patents are given to 
inventors that have “invented or discovered and asexually reproduced a distinct and 
new variety of plant, other than a tuber propagated plant or a plant found in an 
uncultivated state.”270 To invent or discover a “distinct and new variety of plant” that 
is not found in nature, researchers must use plant DNA, similar to the process 
researchers use to extract gene sequences from human DNA.271   
Arguably, if plant patents are categorized as a separate patent type, gene patents 
should be categorized as a separate patent type as well.272 If the USPTO allows 
researchers to patent extracted plant DNA gene sequences that are not found in 
nature as regulated by plant patents, then gene patents should be categorized in a 
similar fashion since the underlying techniques and scientific mechanisms are so 
similar. Therefore, the AIA should, using the plant patent category as a model, 
establish a fourth patent category specifically engineered to regulate and promote 
gene patents.  
B.  A Reduction in Patent Protection to Implement Collaboration  
In addition to creating a fourth patent category for gene patents, additional 
guidelines should be established to implement a shorter protection period to promote 
scientific collaboration, and in turn, stimulate faster discoveries. To achieve the 
maximum benefits from research, a collaboration system must be implemented to 
emphasize the need for data sharing.273   
As stated by the National Research Council (NRC) in 2003: 
Community standards for sharing publication-related data and materials 
should flow from the general principle that the publication of scientific 
information is intended to move science forward.  More specifically, the 
act of publishing is a large quid pro quo in which authors receive credit 
and acknowledgement in exchange for disclosure of their scientific 
findings.  An author’s obligation is not only to release data and materials 
to enable others to verify or replicate published findings but also to 
provide them in a form on which other scientists can build with further 
research.  All members of the scientific community – whether working in 
academia, government, or a commercial enterprise – have equal 
responsibility for upholding community standards as participants in the 
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publication system, and all should be equally able to derive benefits from 
it.274  
Collaboration is a key element to the success of scientific research.  Patents by 
definition “exclude others from making, using, offering for sale, or selling [an] 
invention [in] the United States.”275 Both utility patents and plant patents provide 
twenty years of protection.276  Only when the patent expires does the patented 
subject matter become public domain.277 Legally excluding others from making or 
using a patented sequence for twenty years significantly prohibits the progression of 
science and the discovery of diagnostic techniques and treatments for diseases, such 
as cancer and ALS.   
It is unnecessary to exclude the scientific community from working with patented 
gene sequences for twenty years. Two of the main reasons scientists seek patents are 
for recognition of their work and to preserve the opportunity to continue working 
with their discovery or invention without the pressure of competition. Neither of 
these functions requires twenty years of protection. Instead of granting a long term 
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of protection, the period of protection should be shortened to ten years with the 
opportunity for researchers to renew for an additional five years pursuant to 
substantial evidence of significant research development, otherwise the term ends, 
and the patented subject matter becomes public domain.   
The HGP was planned to last fifteen years but only took thirteen years.278 The 
key to the success of the HGP was collaboration. If the HGP, through a collaborative 
effort, discovered 20,500 genes of the human genome, then it is reasonable to 
assume that any researcher, through collaborative efforts, can make substantial 
progress in research to renew patent protection for an additional five years.279 If a 
researcher cannot provide evidence to show substantial progress then the patented 
gene sequence should become public domain to give others the opportunity to study 
the previously patented subject matter.    
C.  GenBank Database  
In addition to creating a new category for gene patents and reducing the duration 
of patent protection to further promote collaboration and scientific progress, 
Congress should implement the GenBank database as a mandatory system within the 
U.S. gene patent system.280  The GenBank is a free, public database sponsored by the 
NIH that houses genome sequences generated by the HGP, the HapMap Project, and 
other scientific research.281 The NIH designed the GenBank “to provide and 
encourage access within the scientific community to the most up to date and 
comprehensive DNA sequence information.”282 By forcing all scientists that obtain a 
gene patent through USPTO to upload their research and findings as they progress 
through the protected patent period to GenBank, a complete international database 
will exist that will influence not only patented projects, but this data base will also 
spark new findings and inventions for new patents.   
GenBank is the key to implementing collaboration into a system that has 
historically and legally prevented it.283 Currently, the NIH has “no restrictions on the 
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use or distribution of the GenBank data” and has no means of assessing claims of 
patented intellectual property.284 The NIH “cannot provide comment or unrestricted 
permission concerning the use, copying, or distribution of the information contained 
in GenBank.”285 This problem can easily be fixed by requiring users to register 
before being able to use the database, tracking the specific sequences and the 
frequency of each user, tracking the contributions users upload, and requiring users 
with patents to provide proof upon submittal, and in turn clearly marking patented 
submissions as patent protected work.286 Protecting patented work and allowing 
researchers to share research in a free, open, and protected environment will allow 
for significant progress in diagnostic and treatment technologies that will save 
millions of lives.    
D.  Patent Pooling  
Potential ramifications of the GenBank database in terms of collaboration include 
the desire of other researchers to partake in a patented project.  To allow for such 
occurrences, the USPTO should implement gene patent pooling within the 
regulations of gene patents.287 “A patent pool is an agreement between two or more 
patent owners to license one or more of their patents to one another or third 
parties.”288 Patent pooling can alternatively be defined as “the aggregation of 
intellectual property rights which are the subject of cross-licensing, whether they are 
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transferred directly by patentee to licensee or through some medium, such as a joint 
venture, set up specifically to administer the patent pool.”289   
Patent pools have played an important role within the U.S. patent system for over 
150 years.290 There is no conceivable reason why this form of patent cannot be 
implemented within gene patent regulations. Patent pools offer greater innovation 
because more individuals can work with patented subject matter.291 This permits 
parallel research because both the patented researcher and the licensed researchers 
can study a patented subject matter, which results in faster discoveries and results.292  
Patent pooling within the realm of gene patents will only further promote scientific 
research and collaboration.  
The AIA needs to be amended to include legislation, as described above, to better 
regulate gene patents.293 The goals of gene patents should not be focused on name 
recognition or monetary purposes but instead on discovering diagnostic tools and 
treatments that will save millions of lives. By implementing guidelines that promote 
collaboration and scientific research, vast innovations and breakthroughs will occur 
and will bring about diagnostic tools and treatments.   
VI.  CONCLUSION  
The AIA is the foremost change in the U.S. patent system since 1952.294 While 
the AIA implements many new regulations within the U.S patent system, no 
regulations were established to better regulate gene patents.295 The Obama 
Administration announced several plans and studies to look into the proper 
regulations for gene and biotechnology; however, this research is not needed as gene 
patents have been a topic of debate within intellectual property, science, and health 
care for the past three decades.296 Instead of wasting more time researching the best 
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practices to regulate gene patents, stricter guidelines need to be implemented within 
the AIA to regulate gene patents, and this implementation needs to occur quickly to 
keep up with the rapidly growing field of genetics.297   
In order for the U.S. patent system to keep up with the rapidly growing field of 
genetics, the following suggestions should be implemented into the AIA to enforce 
stricter guidelines for gene patents: (1) a new category within the patent system 
should be created specifically for gene patents, as modeled from plant patents;298 (2) 
the period of gene patent protection should be reduced from twenty years to ten 
years, with the potential to renew for an additional five years through a showing of 
substantial scientific progress, to promote collaboration and faster results as seen 
through the HGP;299 (3) individuals that acquire gene patents must be required to 
share their research on the GenBank database to further promote collaboration and 
faster results, not only within the United States, but also internationally;300 and, (4) 
the AIA needs to implement patent pooling for gene patents as a means to support 
collaboration and the use of the GenBank, as well as promote faster results.301 By 
implementing such regulations into the AIA, more scientific breakthroughs will 
occur, which will result in the discovery of new diagnostic technologies and 
treatments, and in turn will save millions of lives from common diseases that were 
once deemed incurable.   
                                                          
297 See supra Part I (discussing advances made in the genetics field). 
298 See supra Part IV.A (discussing creation of a new patent category). 
299 See supra Part IV.B (discussing rationale for this reduction). 
300 See supra Part IV.C. 
301 See JEANNE CLARK ET AL., supra note 288, at 11. 
 
